Drugs / Sulbactam-durlobactam
re-read 2 minutes ago

Sulbactam-durlobactam

Developed for
pulmonary non-tuberculous mycobacterial infection
Investigated by
Innoviva Specialty Therapeutics · The University of Queensland

Trials 1 · a red edge is where a trial was stopped

2028202920302031
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07485010 Apr 2027 → Apr 2031 expected pulmonary non-tuberculous mycobacterial infection The University of Queensland Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Sulbactam-durlobactam “IV sulbactam/durlobactam Greater than or equal to 130ml/min Every FOUR (4) hourly. Administered by intravenous infusion over 3 hours.” NCT07485010
Route Intravenous “Administered by intravenous infusion over 3 hours.” NCT07485010